Dr. Tanya Petrossian, after a challenging journey through misdiagnosis, founded EndoCyclic Therapeutics to address endometriosis, a condition affecting millions but often overlooked. The company recently achieved FDA clearance for its Investigational New Drug application, positioning it to enter Phase 1 clinical trials for a non-hormonal peptide therapy aimed at targeting endometriosis lesions. Additionally, they developed FemLUNA, a non-invasive imaging diagnostic for endometriosis, designed to enhance diagnosis accuracy over traditional methods. Petrossian aims to transform treatment and diagnostics for endometriosis and explore broader applications in women’s health.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ocbj.com/healthcare/irvine-biotech-firm-targets-endometriosis-with-new-therapy/
